CD19 and lymphoma: A previous study using a CD19-loss lymphoma xenograft model found that CD19/CD79a dual-targeting CAR-T cells with different designs (tandem, bicistronic, and coadministration) were effective in preventing the recurrence of CD19-negative tumors at a relatively low required effective dose [46].